VistaGen Therapeutics (NASDAQ: VTGN)
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-09 | ||||||
REV |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.100 | ||||||
REV | 310.100K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of VistaGen Therapeutics (NASDAQ: VTGN) through any online brokerage.
Other companies in VistaGen Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), Cellectar Biosciences (NASDAQ:CLRB), Larimar Therapeutics (NASDAQ:LRMR), Galera Therapeutics (NASDAQ:GRTX) and Trevena (NASDAQ:TRVN).
The latest price target for VistaGen Therapeutics (NASDAQ: VTGN) was reported by Maxim Group on Tuesday, July 26, 2022. The analyst firm set a price target for 0.00 expecting VTGN to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
The stock price for VistaGen Therapeutics (NASDAQ: VTGN) is $0.175 last updated Today at August 11, 2022, 8:00 PM UTC.
There are no upcoming dividends for VistaGen Therapeutics.
VistaGen Therapeutics’s Q2 earnings are confirmed for Wednesday, November 9, 2022.
There is no upcoming split for VistaGen Therapeutics.
VistaGen Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.